0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Oral Medicines for Diabetes Market Research Report 2025
Published Date: May 2025
|
Report Code: QYRE-Auto-35U14058
Home | Market Reports | Health| Health Conditions| Endocrine Conditions
Global Oral Medicines for Diabetes Market Research Report 2023
BUY CHAPTERS

Global Oral Medicines for Diabetes Market Research Report 2025

Code: QYRE-Auto-35U14058
Report
May 2025
Pages:101
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Oral Medicines for Diabetes Market Size

The global market for Oral Medicines for Diabetes was valued at US$ 70480 million in the year 2024 and is projected to reach a revised size of US$ 142020 million by 2031, growing at a CAGR of 10.7% during the forecast period.

Oral Medicines for Diabetes Market

Oral Medicines for Diabetes Market

Oral medications for diabetes are medications that are taken by mouth to manage blood sugar levels in people with type 2 diabetes.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Oral Medicines for Diabetes, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oral Medicines for Diabetes.
The Oral Medicines for Diabetes market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Oral Medicines for Diabetes market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oral Medicines for Diabetes manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Oral Medicines for Diabetes Market Report

Report Metric Details
Report Name Oral Medicines for Diabetes Market
Accounted market size in year US$ 70480 million
Forecasted market size in 2031 US$ 142020 million
CAGR 10.7%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
Segment by Application
  • Hospital
  • Clinic
  • Other
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Bayer, Merck, Novartis, Huadong Medicine, Sanofi, Novo Nordisk, Servier, Takeda Pharmaceutical, Luye Pharmaceutical, Taiji Group, CR Double-Crane, AstraZeneca, Boehringer Ingelheim, Qilu Pharmaceutical, Jiangsu Deyuan Pharmaceutical, CTTQ
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Oral Medicines for Diabetes manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Oral Medicines for Diabetes in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

How fast is Oral Medicines for Diabetes Market growing?

Ans: The Oral Medicines for Diabetes Market witnessing a CAGR of 10.7% during the forecast period 2025-2031.

What is the Oral Medicines for Diabetes Market size in 2031?

Ans: The Oral Medicines for Diabetes Market size in 2031 will be US$ 142020 million.

Who are the main players in the Oral Medicines for Diabetes Market report?

Ans: The main players in the Oral Medicines for Diabetes Market are Bayer, Merck, Novartis, Huadong Medicine, Sanofi, Novo Nordisk, Servier, Takeda Pharmaceutical, Luye Pharmaceutical, Taiji Group, CR Double-Crane, AstraZeneca, Boehringer Ingelheim, Qilu Pharmaceutical, Jiangsu Deyuan Pharmaceutical, CTTQ

What are the Application segmentation covered in the Oral Medicines for Diabetes Market report?

Ans: The Applications covered in the Oral Medicines for Diabetes Market report are Hospital, Clinic, Other

What are the Type segmentation covered in the Oral Medicines for Diabetes Market report?

Ans: The Types covered in the Oral Medicines for Diabetes Market report are Biguanides, Sulfonylureas, Meglitinides, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, SGLT2 Inhibitors, Thiazolidinediones, Alpha-Glucosidase Inhibitors, Other

Recommended Reports

Oral Antidiabetic Drugs

Oral & Metabolic Medicines

Broader Oral Medicines

1 Oral Medicines for Diabetes Market Overview
1.1 Product Definition
1.2 Oral Medicines for Diabetes by Type
1.2.1 Global Oral Medicines for Diabetes Market Value Comparison by Type (2024 VS 2031)
1.2.2 Biguanides
1.2.3 Sulfonylureas
1.2.4 Meglitinides
1.2.5 Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
1.2.6 SGLT2 Inhibitors
1.2.7 Thiazolidinediones
1.2.8 Alpha-Glucosidase Inhibitors
1.2.9 Other
1.3 Oral Medicines for Diabetes by Application
1.3.1 Global Oral Medicines for Diabetes Market Value by Application (2024 VS 2031)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Global Oral Medicines for Diabetes Market Size Estimates and Forecasts
1.4.1 Global Oral Medicines for Diabetes Revenue 2020-2031
1.4.2 Global Oral Medicines for Diabetes Sales 2020-2031
1.4.3 Global Oral Medicines for Diabetes Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Oral Medicines for Diabetes Market Competition by Manufacturers
2.1 Global Oral Medicines for Diabetes Sales Market Share by Manufacturers (2020-2025)
2.2 Global Oral Medicines for Diabetes Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Oral Medicines for Diabetes Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Oral Medicines for Diabetes, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Oral Medicines for Diabetes, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Oral Medicines for Diabetes, Product Type & Application
2.7 Global Key Manufacturers of Oral Medicines for Diabetes, Date of Enter into This Industry
2.8 Global Oral Medicines for Diabetes Market Competitive Situation and Trends
2.8.1 Global Oral Medicines for Diabetes Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Oral Medicines for Diabetes Players Market Share by Revenue
2.8.3 Global Oral Medicines for Diabetes Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Oral Medicines for Diabetes Market Scenario by Region
3.1 Global Oral Medicines for Diabetes Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Oral Medicines for Diabetes Sales by Region: 2020-2031
3.2.1 Global Oral Medicines for Diabetes Sales by Region: 2020-2025
3.2.2 Global Oral Medicines for Diabetes Sales by Region: 2026-2031
3.3 Global Oral Medicines for Diabetes Revenue by Region: 2020-2031
3.3.1 Global Oral Medicines for Diabetes Revenue by Region: 2020-2025
3.3.2 Global Oral Medicines for Diabetes Revenue by Region: 2026-2031
3.4 North America Oral Medicines for Diabetes Market Facts & Figures by Country
3.4.1 North America Oral Medicines for Diabetes Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Oral Medicines for Diabetes Sales by Country (2020-2031)
3.4.3 North America Oral Medicines for Diabetes Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Oral Medicines for Diabetes Market Facts & Figures by Country
3.5.1 Europe Oral Medicines for Diabetes Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Oral Medicines for Diabetes Sales by Country (2020-2031)
3.5.3 Europe Oral Medicines for Diabetes Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Oral Medicines for Diabetes Market Facts & Figures by Region
3.6.1 Asia Pacific Oral Medicines for Diabetes Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Oral Medicines for Diabetes Sales by Region (2020-2031)
3.6.3 Asia Pacific Oral Medicines for Diabetes Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Oral Medicines for Diabetes Market Facts & Figures by Country
3.7.1 Latin America Oral Medicines for Diabetes Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Oral Medicines for Diabetes Sales by Country (2020-2031)
3.7.3 Latin America Oral Medicines for Diabetes Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Oral Medicines for Diabetes Market Facts & Figures by Country
3.8.1 Middle East and Africa Oral Medicines for Diabetes Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Oral Medicines for Diabetes Sales by Country (2020-2031)
3.8.3 Middle East and Africa Oral Medicines for Diabetes Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Oral Medicines for Diabetes Sales by Type (2020-2031)
4.1.1 Global Oral Medicines for Diabetes Sales by Type (2020-2025)
4.1.2 Global Oral Medicines for Diabetes Sales by Type (2026-2031)
4.1.3 Global Oral Medicines for Diabetes Sales Market Share by Type (2020-2031)
4.2 Global Oral Medicines for Diabetes Revenue by Type (2020-2031)
4.2.1 Global Oral Medicines for Diabetes Revenue by Type (2020-2025)
4.2.2 Global Oral Medicines for Diabetes Revenue by Type (2026-2031)
4.2.3 Global Oral Medicines for Diabetes Revenue Market Share by Type (2020-2031)
4.3 Global Oral Medicines for Diabetes Price by Type (2020-2031)
5 Segment by Application
5.1 Global Oral Medicines for Diabetes Sales by Application (2020-2031)
5.1.1 Global Oral Medicines for Diabetes Sales by Application (2020-2025)
5.1.2 Global Oral Medicines for Diabetes Sales by Application (2026-2031)
5.1.3 Global Oral Medicines for Diabetes Sales Market Share by Application (2020-2031)
5.2 Global Oral Medicines for Diabetes Revenue by Application (2020-2031)
5.2.1 Global Oral Medicines for Diabetes Revenue by Application (2020-2025)
5.2.2 Global Oral Medicines for Diabetes Revenue by Application (2026-2031)
5.2.3 Global Oral Medicines for Diabetes Revenue Market Share by Application (2020-2031)
5.3 Global Oral Medicines for Diabetes Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Bayer
6.1.1 Bayer Company Information
6.1.2 Bayer Description and Business Overview
6.1.3 Bayer Oral Medicines for Diabetes Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Bayer Oral Medicines for Diabetes Product Portfolio
6.1.5 Bayer Recent Developments/Updates
6.2 Merck
6.2.1 Merck Company Information
6.2.2 Merck Description and Business Overview
6.2.3 Merck Oral Medicines for Diabetes Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Merck Oral Medicines for Diabetes Product Portfolio
6.2.5 Merck Recent Developments/Updates
6.3 Novartis
6.3.1 Novartis Company Information
6.3.2 Novartis Description and Business Overview
6.3.3 Novartis Oral Medicines for Diabetes Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Novartis Oral Medicines for Diabetes Product Portfolio
6.3.5 Novartis Recent Developments/Updates
6.4 Huadong Medicine
6.4.1 Huadong Medicine Company Information
6.4.2 Huadong Medicine Description and Business Overview
6.4.3 Huadong Medicine Oral Medicines for Diabetes Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Huadong Medicine Oral Medicines for Diabetes Product Portfolio
6.4.5 Huadong Medicine Recent Developments/Updates
6.5 Sanofi
6.5.1 Sanofi Company Information
6.5.2 Sanofi Description and Business Overview
6.5.3 Sanofi Oral Medicines for Diabetes Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Sanofi Oral Medicines for Diabetes Product Portfolio
6.5.5 Sanofi Recent Developments/Updates
6.6 Novo Nordisk
6.6.1 Novo Nordisk Company Information
6.6.2 Novo Nordisk Description and Business Overview
6.6.3 Novo Nordisk Oral Medicines for Diabetes Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Novo Nordisk Oral Medicines for Diabetes Product Portfolio
6.6.5 Novo Nordisk Recent Developments/Updates
6.7 Servier
6.7.1 Servier Company Information
6.7.2 Servier Description and Business Overview
6.7.3 Servier Oral Medicines for Diabetes Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Servier Oral Medicines for Diabetes Product Portfolio
6.7.5 Servier Recent Developments/Updates
6.8 Takeda Pharmaceutical
6.8.1 Takeda Pharmaceutical Company Information
6.8.2 Takeda Pharmaceutical Description and Business Overview
6.8.3 Takeda Pharmaceutical Oral Medicines for Diabetes Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Takeda Pharmaceutical Oral Medicines for Diabetes Product Portfolio
6.8.5 Takeda Pharmaceutical Recent Developments/Updates
6.9 Luye Pharmaceutical
6.9.1 Luye Pharmaceutical Company Information
6.9.2 Luye Pharmaceutical Description and Business Overview
6.9.3 Luye Pharmaceutical Oral Medicines for Diabetes Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Luye Pharmaceutical Oral Medicines for Diabetes Product Portfolio
6.9.5 Luye Pharmaceutical Recent Developments/Updates
6.10 Taiji Group
6.10.1 Taiji Group Company Information
6.10.2 Taiji Group Description and Business Overview
6.10.3 Taiji Group Oral Medicines for Diabetes Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Taiji Group Oral Medicines for Diabetes Product Portfolio
6.10.5 Taiji Group Recent Developments/Updates
6.11 CR Double-Crane
6.11.1 CR Double-Crane Company Information
6.11.2 CR Double-Crane Description and Business Overview
6.11.3 CR Double-Crane Oral Medicines for Diabetes Sales, Revenue and Gross Margin (2020-2025)
6.11.4 CR Double-Crane Oral Medicines for Diabetes Product Portfolio
6.11.5 CR Double-Crane Recent Developments/Updates
6.12 AstraZeneca
6.12.1 AstraZeneca Company Information
6.12.2 AstraZeneca Description and Business Overview
6.12.3 AstraZeneca Oral Medicines for Diabetes Sales, Revenue and Gross Margin (2020-2025)
6.12.4 AstraZeneca Oral Medicines for Diabetes Product Portfolio
6.12.5 AstraZeneca Recent Developments/Updates
6.13 Boehringer Ingelheim
6.13.1 Boehringer Ingelheim Company Information
6.13.2 Boehringer Ingelheim Description and Business Overview
6.13.3 Boehringer Ingelheim Oral Medicines for Diabetes Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Boehringer Ingelheim Oral Medicines for Diabetes Product Portfolio
6.13.5 Boehringer Ingelheim Recent Developments/Updates
6.14 Qilu Pharmaceutical
6.14.1 Qilu Pharmaceutical Company Information
6.14.2 Qilu Pharmaceutical Description and Business Overview
6.14.3 Qilu Pharmaceutical Oral Medicines for Diabetes Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Qilu Pharmaceutical Oral Medicines for Diabetes Product Portfolio
6.14.5 Qilu Pharmaceutical Recent Developments/Updates
6.15 Jiangsu Deyuan Pharmaceutical
6.15.1 Jiangsu Deyuan Pharmaceutical Company Information
6.15.2 Jiangsu Deyuan Pharmaceutical Description and Business Overview
6.15.3 Jiangsu Deyuan Pharmaceutical Oral Medicines for Diabetes Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Jiangsu Deyuan Pharmaceutical Oral Medicines for Diabetes Product Portfolio
6.15.5 Jiangsu Deyuan Pharmaceutical Recent Developments/Updates
6.16 CTTQ
6.16.1 CTTQ Company Information
6.16.2 CTTQ Description and Business Overview
6.16.3 CTTQ Oral Medicines for Diabetes Sales, Revenue and Gross Margin (2020-2025)
6.16.4 CTTQ Oral Medicines for Diabetes Product Portfolio
6.16.5 CTTQ Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Oral Medicines for Diabetes Industry Chain Analysis
7.2 Oral Medicines for Diabetes Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Oral Medicines for Diabetes Production Mode & Process Analysis
7.4 Oral Medicines for Diabetes Sales and Marketing
7.4.1 Oral Medicines for Diabetes Sales Channels
7.4.2 Oral Medicines for Diabetes Distributors
7.5 Oral Medicines for Diabetes Customer Analysis
8 Oral Medicines for Diabetes Market Dynamics
8.1 Oral Medicines for Diabetes Industry Trends
8.2 Oral Medicines for Diabetes Market Drivers
8.3 Oral Medicines for Diabetes Market Challenges
8.4 Oral Medicines for Diabetes Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global Oral Medicines for Diabetes Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Oral Medicines for Diabetes Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Oral Medicines for Diabetes Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Oral Medicines for Diabetes Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Oral Medicines for Diabetes Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Oral Medicines for Diabetes Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Oral Medicines for Diabetes Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Oral Medicines for Diabetes Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Oral Medicines for Diabetes, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Oral Medicines for Diabetes, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Oral Medicines for Diabetes, Product Type & Application
 Table 12. Global Key Manufacturers of Oral Medicines for Diabetes, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Oral Medicines for Diabetes by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oral Medicines for Diabetes as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Oral Medicines for Diabetes Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Oral Medicines for Diabetes Sales by Region (2020-2025) & (K Units)
 Table 18. Global Oral Medicines for Diabetes Sales Market Share by Region (2020-2025)
 Table 19. Global Oral Medicines for Diabetes Sales by Region (2026-2031) & (K Units)
 Table 20. Global Oral Medicines for Diabetes Sales Market Share by Region (2026-2031)
 Table 21. Global Oral Medicines for Diabetes Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Oral Medicines for Diabetes Revenue Market Share by Region (2020-2025)
 Table 23. Global Oral Medicines for Diabetes Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Oral Medicines for Diabetes Revenue Market Share by Region (2026-2031)
 Table 25. North America Oral Medicines for Diabetes Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Oral Medicines for Diabetes Sales by Country (2020-2025) & (K Units)
 Table 27. North America Oral Medicines for Diabetes Sales by Country (2026-2031) & (K Units)
 Table 28. North America Oral Medicines for Diabetes Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Oral Medicines for Diabetes Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Oral Medicines for Diabetes Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Oral Medicines for Diabetes Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Oral Medicines for Diabetes Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Oral Medicines for Diabetes Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Oral Medicines for Diabetes Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Oral Medicines for Diabetes Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Oral Medicines for Diabetes Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Oral Medicines for Diabetes Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Oral Medicines for Diabetes Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Oral Medicines for Diabetes Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Oral Medicines for Diabetes Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Oral Medicines for Diabetes Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Oral Medicines for Diabetes Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Oral Medicines for Diabetes Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Oral Medicines for Diabetes Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Oral Medicines for Diabetes Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Oral Medicines for Diabetes Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Oral Medicines for Diabetes Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Oral Medicines for Diabetes Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Oral Medicines for Diabetes Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Oral Medicines for Diabetes Sales (K Units) by Type (2020-2025)
 Table 51. Global Oral Medicines for Diabetes Sales (K Units) by Type (2026-2031)
 Table 52. Global Oral Medicines for Diabetes Sales Market Share by Type (2020-2025)
 Table 53. Global Oral Medicines for Diabetes Sales Market Share by Type (2026-2031)
 Table 54. Global Oral Medicines for Diabetes Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Oral Medicines for Diabetes Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Oral Medicines for Diabetes Revenue Market Share by Type (2020-2025)
 Table 57. Global Oral Medicines for Diabetes Revenue Market Share by Type (2026-2031)
 Table 58. Global Oral Medicines for Diabetes Price (US$/Unit) by Type (2020-2025)
 Table 59. Global Oral Medicines for Diabetes Price (US$/Unit) by Type (2026-2031)
 Table 60. Global Oral Medicines for Diabetes Sales (K Units) by Application (2020-2025)
 Table 61. Global Oral Medicines for Diabetes Sales (K Units) by Application (2026-2031)
 Table 62. Global Oral Medicines for Diabetes Sales Market Share by Application (2020-2025)
 Table 63. Global Oral Medicines for Diabetes Sales Market Share by Application (2026-2031)
 Table 64. Global Oral Medicines for Diabetes Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Oral Medicines for Diabetes Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Oral Medicines for Diabetes Revenue Market Share by Application (2020-2025)
 Table 67. Global Oral Medicines for Diabetes Revenue Market Share by Application (2026-2031)
 Table 68. Global Oral Medicines for Diabetes Price (US$/Unit) by Application (2020-2025)
 Table 69. Global Oral Medicines for Diabetes Price (US$/Unit) by Application (2026-2031)
 Table 70. Bayer Company Information
 Table 71. Bayer Description and Business Overview
 Table 72. Bayer Oral Medicines for Diabetes Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. Bayer Oral Medicines for Diabetes Product
 Table 74. Bayer Recent Developments/Updates
 Table 75. Merck Company Information
 Table 76. Merck Description and Business Overview
 Table 77. Merck Oral Medicines for Diabetes Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. Merck Oral Medicines for Diabetes Product
 Table 79. Merck Recent Developments/Updates
 Table 80. Novartis Company Information
 Table 81. Novartis Description and Business Overview
 Table 82. Novartis Oral Medicines for Diabetes Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. Novartis Oral Medicines for Diabetes Product
 Table 84. Novartis Recent Developments/Updates
 Table 85. Huadong Medicine Company Information
 Table 86. Huadong Medicine Description and Business Overview
 Table 87. Huadong Medicine Oral Medicines for Diabetes Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. Huadong Medicine Oral Medicines for Diabetes Product
 Table 89. Huadong Medicine Recent Developments/Updates
 Table 90. Sanofi Company Information
 Table 91. Sanofi Description and Business Overview
 Table 92. Sanofi Oral Medicines for Diabetes Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. Sanofi Oral Medicines for Diabetes Product
 Table 94. Sanofi Recent Developments/Updates
 Table 95. Novo Nordisk Company Information
 Table 96. Novo Nordisk Description and Business Overview
 Table 97. Novo Nordisk Oral Medicines for Diabetes Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. Novo Nordisk Oral Medicines for Diabetes Product
 Table 99. Novo Nordisk Recent Developments/Updates
 Table 100. Servier Company Information
 Table 101. Servier Description and Business Overview
 Table 102. Servier Oral Medicines for Diabetes Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 103. Servier Oral Medicines for Diabetes Product
 Table 104. Servier Recent Developments/Updates
 Table 105. Takeda Pharmaceutical Company Information
 Table 106. Takeda Pharmaceutical Description and Business Overview
 Table 107. Takeda Pharmaceutical Oral Medicines for Diabetes Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 108. Takeda Pharmaceutical Oral Medicines for Diabetes Product
 Table 109. Takeda Pharmaceutical Recent Developments/Updates
 Table 110. Luye Pharmaceutical Company Information
 Table 111. Luye Pharmaceutical Description and Business Overview
 Table 112. Luye Pharmaceutical Oral Medicines for Diabetes Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 113. Luye Pharmaceutical Oral Medicines for Diabetes Product
 Table 114. Luye Pharmaceutical Recent Developments/Updates
 Table 115. Taiji Group Company Information
 Table 116. Taiji Group Description and Business Overview
 Table 117. Taiji Group Oral Medicines for Diabetes Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 118. Taiji Group Oral Medicines for Diabetes Product
 Table 119. Taiji Group Recent Developments/Updates
 Table 120. CR Double-Crane Company Information
 Table 121. CR Double-Crane Description and Business Overview
 Table 122. CR Double-Crane Oral Medicines for Diabetes Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 123. CR Double-Crane Oral Medicines for Diabetes Product
 Table 124. CR Double-Crane Recent Developments/Updates
 Table 125. AstraZeneca Company Information
 Table 126. AstraZeneca Description and Business Overview
 Table 127. AstraZeneca Oral Medicines for Diabetes Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 128. AstraZeneca Oral Medicines for Diabetes Product
 Table 129. AstraZeneca Recent Developments/Updates
 Table 130. Boehringer Ingelheim Company Information
 Table 131. Boehringer Ingelheim Description and Business Overview
 Table 132. Boehringer Ingelheim Oral Medicines for Diabetes Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 133. Boehringer Ingelheim Oral Medicines for Diabetes Product
 Table 134. Boehringer Ingelheim Recent Developments/Updates
 Table 135. Qilu Pharmaceutical Company Information
 Table 136. Qilu Pharmaceutical Description and Business Overview
 Table 137. Qilu Pharmaceutical Oral Medicines for Diabetes Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 138. Qilu Pharmaceutical Oral Medicines for Diabetes Product
 Table 139. Qilu Pharmaceutical Recent Developments/Updates
 Table 140. Jiangsu Deyuan Pharmaceutical Company Information
 Table 141. Jiangsu Deyuan Pharmaceutical Description and Business Overview
 Table 142. Jiangsu Deyuan Pharmaceutical Oral Medicines for Diabetes Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 143. Jiangsu Deyuan Pharmaceutical Oral Medicines for Diabetes Product
 Table 144. Jiangsu Deyuan Pharmaceutical Recent Developments/Updates
 Table 145. CTTQ Company Information
 Table 146. CTTQ Description and Business Overview
 Table 147. CTTQ Oral Medicines for Diabetes Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 148. CTTQ Oral Medicines for Diabetes Product
 Table 149. CTTQ Recent Developments/Updates
 Table 150. Key Raw Materials Lists
 Table 151. Raw Materials Key Suppliers Lists
 Table 152. Oral Medicines for Diabetes Distributors List
 Table 153. Oral Medicines for Diabetes Customers List
 Table 154. Oral Medicines for Diabetes Market Trends
 Table 155. Oral Medicines for Diabetes Market Drivers
 Table 156. Oral Medicines for Diabetes Market Challenges
 Table 157. Oral Medicines for Diabetes Market Restraints
 Table 158. Research Programs/Design for This Report
 Table 159. Key Data Information from Secondary Sources
 Table 160. Key Data Information from Primary Sources
 Table 161. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Oral Medicines for Diabetes
 Figure 2. Global Oral Medicines for Diabetes Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Oral Medicines for Diabetes Market Share by Type: 2024 & 2031
 Figure 4. Biguanides Product Picture
 Figure 5. Sulfonylureas Product Picture
 Figure 6. Meglitinides Product Picture
 Figure 7. Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Product Picture
 Figure 8. SGLT2 Inhibitors Product Picture
 Figure 9. Thiazolidinediones Product Picture
 Figure 10. Alpha-Glucosidase Inhibitors Product Picture
 Figure 11. Other Product Picture
 Figure 12. Global Oral Medicines for Diabetes Market Value by Application (2020-2031) & (US$ Million)
 Figure 13. Global Oral Medicines for Diabetes Market Share by Application: 2024 & 2031
 Figure 14. Hospital
 Figure 15. Clinic
 Figure 16. Other
 Figure 17. Global Oral Medicines for Diabetes Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 18. Global Oral Medicines for Diabetes Market Size (2020-2031) & (US$ Million)
 Figure 19. Global Oral Medicines for Diabetes Sales (2020-2031) & (K Units)
 Figure 20. Global Oral Medicines for Diabetes Average Price (US$/Unit) & (2020-2031)
 Figure 21. Oral Medicines for Diabetes Report Years Considered
 Figure 22. Oral Medicines for Diabetes Sales Share by Manufacturers in 2024
 Figure 23. Global Oral Medicines for Diabetes Revenue Share by Manufacturers in 2024
 Figure 24. Global 5 and 10 Largest Oral Medicines for Diabetes Players: Market Share by Revenue in Oral Medicines for Diabetes in 2024
 Figure 25. Oral Medicines for Diabetes Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 26. Global Oral Medicines for Diabetes Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 27. North America Oral Medicines for Diabetes Sales Market Share by Country (2020-2031)
 Figure 28. North America Oral Medicines for Diabetes Revenue Market Share by Country (2020-2031)
 Figure 29. United States Oral Medicines for Diabetes Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. Canada Oral Medicines for Diabetes Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Europe Oral Medicines for Diabetes Sales Market Share by Country (2020-2031)
 Figure 32. Europe Oral Medicines for Diabetes Revenue Market Share by Country (2020-2031)
 Figure 33. Germany Oral Medicines for Diabetes Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. France Oral Medicines for Diabetes Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. U.K. Oral Medicines for Diabetes Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. Italy Oral Medicines for Diabetes Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. Russia Oral Medicines for Diabetes Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. Asia Pacific Oral Medicines for Diabetes Sales Market Share by Region (2020-2031)
 Figure 39. Asia Pacific Oral Medicines for Diabetes Revenue Market Share by Region (2020-2031)
 Figure 40. China Oral Medicines for Diabetes Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Japan Oral Medicines for Diabetes Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. South Korea Oral Medicines for Diabetes Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. India Oral Medicines for Diabetes Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Australia Oral Medicines for Diabetes Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. China Taiwan Oral Medicines for Diabetes Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Southeast Asia Oral Medicines for Diabetes Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Latin America Oral Medicines for Diabetes Sales Market Share by Country (2020-2031)
 Figure 48. Latin America Oral Medicines for Diabetes Revenue Market Share by Country (2020-2031)
 Figure 49. Mexico Oral Medicines for Diabetes Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. Brazil Oral Medicines for Diabetes Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Argentina Oral Medicines for Diabetes Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. Middle East and Africa Oral Medicines for Diabetes Sales Market Share by Country (2020-2031)
 Figure 53. Middle East and Africa Oral Medicines for Diabetes Revenue Market Share by Country (2020-2031)
 Figure 54. Turkey Oral Medicines for Diabetes Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 55. Saudi Arabia Oral Medicines for Diabetes Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 56. UAE Oral Medicines for Diabetes Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 57. Global Sales Market Share of Oral Medicines for Diabetes by Type (2020-2031)
 Figure 58. Global Revenue Market Share of Oral Medicines for Diabetes by Type (2020-2031)
 Figure 59. Global Oral Medicines for Diabetes Price (US$/Unit) by Type (2020-2031)
 Figure 60. Global Sales Market Share of Oral Medicines for Diabetes by Application (2020-2031)
 Figure 61. Global Revenue Market Share of Oral Medicines for Diabetes by Application (2020-2031)
 Figure 62. Global Oral Medicines for Diabetes Price (US$/Unit) by Application (2020-2031)
 Figure 63. Oral Medicines for Diabetes Value Chain
 Figure 64. Channels of Distribution (Direct Vs Distribution)
 Figure 65. Bottom-up and Top-down Approaches for This Report
 Figure 66. Data Triangulation
 Figure 67. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Nano Dimension

SIMILAR REPORTS